{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:31:55Z","timestamp":1785929515527,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Leucine-rich alpha-2-glycoprotein 1 (LRG1) was previously reported to regulate inflammation and arthritis progression. This study aimed to investigate the correlation of serum LRG1 level with disease features and response to biologics in rheumatoid arthritis (RA) patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Seventy-eight RA patients who underwent biologics treatment were analyzed. Serum LRG1 level was detected by enzyme-linked immunosorbent assay at baseline (before biologics were initiated) and at weeks 6 and 12. Treatment response, low disease activity (LDA), and remission were analyzed on the basis of disease activity score in 28 joints. Moreover, serum LRG1 level in another 20 health controls was also analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>LRG1 was greater in RA patients than in health controls (46.3 versus 28.6 \u00b5g\/mL, <jats:italic>P<\/jats:italic> &lt; 0.001), with an area under the curve of 0.795 for differentiating them according to the receiver operator characteristic curve. By correlation analysis, LRG1 was correlated with a greater body mass index (<jats:italic>P<\/jats:italic> = 0.007) and C-reactive protein level (<jats:italic>P<\/jats:italic> = 0.013) in RA patients and tended to be associated with swollen joint count but was not statistically significant (<jats:italic>P<\/jats:italic> = 0.052). Furthermore, LRG1 decreased from baseline to week 12 after biologics treatment in RA patients (<jats:italic>P<\/jats:italic> &lt; 0.001). However, baseline LRG1 was not correlated with treatment response (<jats:italic>P<\/jats:italic> = 0.987), LDA (<jats:italic>P<\/jats:italic> = 0.405), or remission (<jats:italic>P<\/jats:italic> = 0.763) in RA patients. A decrease in LRG1 at week 12 (<jats:italic>P<\/jats:italic> = 0.028) was related to response achievement, and a decrease in LRG1 at week 6 (<jats:italic>P<\/jats:italic> = 0.047) and week 12 (<jats:italic>P<\/jats:italic> = 0.019) was related to LDA achievement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>LRG1 may aid in RA disease supervision, but further validation is needed.<\/jats:p>\n            <jats:p>\n              <jats:table-wrap>\n                <jats:table>\n                  <jats:tbody>\n                    <jats:tr>\n                      <jats:td align=\"left\" colspan=\"2\">\n                        <jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>LRG1 level can distinguish RA patients from health controls with a high AUC at 0.795.<\/jats:italic>\u2022 <jats:italic>LRG1 level is correlated with higher BMI and CRP level, and tends to be related to elevated SJC in RA patients.<\/jats:italic>\u2022 <jats:italic>LRG1 level after treatment is correlated with clinical response and LDA to biologics in RA patients, while its level before treatment fails to do so.<\/jats:italic>\u2022 <jats:italic>Collectively, LRG1 level shows a potential to be a biomarker for RA disease supervision.<\/jats:italic>\n                      <\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody>\n                <\/jats:table>\n              <\/jats:table-wrap>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10067-025-07545-2","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:49:55Z","timestamp":1752612595000},"page":"3391-3398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leucine-rich alpha-2-glycoprotein 1 (LRG1) decrement during biologics therapy and its correlation with disease features and treatment outcomes in rheumatoid arthritis patients"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2101-0521","authenticated-orcid":false,"given":"Liang","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"10416","key":"7545_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P (2023) Rheumatoid arthritis. Lancet 402(10416):2019\u20132033. https:\/\/doi.org\/10.1016\/S0140-6736(23)01525-8","journal-title":"Lancet"},{"issue":"5","key":"7545_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"K Almutairi","year":"2021","unstructured":"Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C (2021) The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 41(5):863\u2013877. https:\/\/doi.org\/10.1007\/s00296-020-04731-0","journal-title":"Rheumatol Int"},{"issue":"1","key":"7545_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7545_CR4","doi-asserted-by":"publisher","first-page":"e33293","DOI":"10.7759\/cureus.33293","volume":"15","author":"JP Patel","year":"2023","unstructured":"Patel JP, Konanur Srinivasa NK, Gande A, Anusha M, Dar H, Baji DB (2023) The role of biologics in rheumatoid arthritis: a narrative review. Cureus 15(1):e33293. https:\/\/doi.org\/10.7759\/cureus.33293","journal-title":"Cureus"},{"key":"7545_CR5","doi-asserted-by":"publisher","first-page":"115434","DOI":"10.1016\/j.ejmech.2023.115434","volume":"256","author":"JH Zhao","year":"2023","unstructured":"Zhao JH, Ma S, Li CY, Zhang HC, Zhao LJ, Zhang ZY (2023) Clinically approved small-molecule drugs for the treatment of rheumatoid arthritis. Eur J Med Chem 256:115434. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115434","journal-title":"Eur J Med Chem"},{"issue":"1","key":"7545_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13075-020-2122-5","volume":"22","author":"S Ochi","year":"2020","unstructured":"Ochi S, Saito K, Mizoguchi F, Kato S, Tanaka Y (2020) Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. Arthritis Res Ther 22(1):41. https:\/\/doi.org\/10.1186\/s13075-020-2122-5","journal-title":"Arthritis Res Ther"},{"key":"7545_CR7","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.2147\/JIR.S284405","volume":"14","author":"L Terslev","year":"2021","unstructured":"Terslev L, Ostergaard M (2021) Rheumatoid arthritis relapse and remission - advancing our predictive capability using modern imaging. J Inflamm Res 14:2547\u20132555. https:\/\/doi.org\/10.2147\/JIR.S284405","journal-title":"J Inflamm Res"},{"issue":"6","key":"7545_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1080\/14397595.2019.1702253","volume":"30","author":"T Naniwa","year":"2020","unstructured":"Naniwa T, Iwagaitsu S, Kajiura M (2020) Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: an observational study in routine clinical care. Mod Rheumatol 30(6):948\u2013958. https:\/\/doi.org\/10.1080\/14397595.2019.1702253","journal-title":"Mod Rheumatol"},{"issue":"1","key":"7545_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/10408363.2020.1775545","volume":"58","author":"E Savvateeva","year":"2021","unstructured":"Savvateeva E, Smoldovskaya O, Feyzkhanova G, Rubina A (2021) Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis. Crit Rev Clin Lab Sci 58(1):17\u201328. https:\/\/doi.org\/10.1080\/10408363.2020.1775545","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"3","key":"7545_CR10","doi-asserted-by":"publisher","first-page":"105066","DOI":"10.1016\/j.jbspin.2020.08.001","volume":"88","author":"E Myasoedova","year":"2021","unstructured":"Myasoedova E (2021) New era for outcomes and management of rheumatoid arthritis: facing the individualized treatment challenge. Joint Bone Spine 88(3):105066. https:\/\/doi.org\/10.1016\/j.jbspin.2020.08.001","journal-title":"Joint Bone Spine"},{"key":"7545_CR11","doi-asserted-by":"publisher","unstructured":"Vuolteenaho K, Tuure L, Nieminen R, Laasonen L, Leirisalo-Repo M, Moilanen E, Group NE-RS (2022) Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab. Scand J Rheumatol 51(3):180\u2013185. https:\/\/doi.org\/10.1080\/03009742.2021.1929456","DOI":"10.1080\/03009742.2021.1929456"},{"issue":"4","key":"7545_CR12","doi-asserted-by":"publisher","first-page":"e23709","DOI":"10.1002\/jcla.23709","volume":"35","author":"L Sun","year":"2021","unstructured":"Sun L, Tu J, Chen X, Dai M, Xia X, Liu C, Zhou Y (2021) JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response. J Clin Lab Anal 35(4):e23709. https:\/\/doi.org\/10.1002\/jcla.23709","journal-title":"J Clin Lab Anal"},{"issue":"1","key":"7545_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12929-022-00790-6","volume":"29","author":"C Camilli","year":"2022","unstructured":"Camilli C, Hoeh AE, De Rossi G, Moss SE, Greenwood J (2022) LRG1: an emerging player in disease pathogenesis. J Biomed Sci 29(1):6. https:\/\/doi.org\/10.1186\/s12929-022-00790-6","journal-title":"J Biomed Sci"},{"issue":"1","key":"7545_CR14","doi-asserted-by":"publisher","first-page":"e0170261","DOI":"10.1371\/journal.pone.0170261","volume":"12","author":"LJ Druhan","year":"2017","unstructured":"Druhan LJ, Lance A, Li S, Price AE, Emerson JT, Baxter SA, Gerber JM, Avalos BR (2017) Leucine rich alpha-2 glycoprotein: a novel neutrophil granule protein and modulator of myelopoiesis. PLoS One 12(1):e0170261. https:\/\/doi.org\/10.1371\/journal.pone.0170261","journal-title":"PLoS One"},{"issue":"11","key":"7545_CR15","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.2337\/db20-0585","volume":"69","author":"C Liu","year":"2020","unstructured":"Liu C, Teo MHY, Pek SLT, Wu X, Leong ML, Tay HM, Hou HW, Ruedl C, Moss SE, Greenwood J, Tavintharan S, Hong W, Wang X (2020) A multifunctional role of leucine-rich alpha-2-glycoprotein 1 in cutaneous wound healing under normal and diabetic conditions. Diabetes 69(11):2467\u20132480. https:\/\/doi.org\/10.2337\/db20-0585","journal-title":"Diabetes"},{"issue":"3","key":"7545_CR16","doi-asserted-by":"publisher","first-page":"C415","DOI":"10.1152\/ajpcell.00517.2020","volume":"321","author":"B Yu","year":"2021","unstructured":"Yu B, Yang L, Song S, Li W, Wang H, Cheng J (2021) LRG1 facilitates corneal fibrotic response by inducing neutrophil chemotaxis via Stat3 signaling in alkali-burned mouse corneas. Am J Physiol Cell Physiol 321(3):C415\u2013C428. https:\/\/doi.org\/10.1152\/ajpcell.00517.2020","journal-title":"Am J Physiol Cell Physiol"},{"issue":"35","key":"7545_CR17","doi-asserted-by":"publisher","first-page":"e2405845121","DOI":"10.1073\/pnas.2405845121","volume":"121","author":"J Wang","year":"2024","unstructured":"Wang J, Wang J, Zhong J, Liu H, Li W, Chen M, Xu L, Zhang W, Zhang Z, Wei Z, Guo J, Wang X, Sui J, Liu X, Zhang S, Wang X (2024) LRG1 promotes atherosclerosis by inducing macrophage M1-like polarization. Proc Natl Acad Sci U S A 121(35):e2405845121. https:\/\/doi.org\/10.1073\/pnas.2405845121","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7545_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13075-017-1349-2","volume":"19","author":"H Urushima","year":"2017","unstructured":"Urushima H, Fujimoto M, Mishima T, Ohkawara T, Honda H, Lee H, Kawahata H, Serada S, Naka T (2017) Leucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF-beta-Smad2 signaling in naive helper T cells. Arthritis Res Ther 19(1):137. https:\/\/doi.org\/10.1186\/s13075-017-1349-2","journal-title":"Arthritis Res Ther"},{"key":"7545_CR19","doi-asserted-by":"publisher","unstructured":"Codina R, Vanasse A, Kelekar A, Vezys V, Jemmerson R (2010) Cytochrome c-induced lymphocyte death from the outside in: inhibition by serum leucine-rich alpha-2-glycoprotein-1. Apoptosis 15 (2):139-152. https:\/\/doi.org\/10.1007\/s10495-009-0412-0","DOI":"10.1007\/s10495-009-0412-0"},{"issue":"4","key":"7545_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.bbrc.2009.03.104","volume":"382","author":"R Shirai","year":"2009","unstructured":"Shirai R, Hirano F, Ohkura N, Ikeda K, Inoue S (2009) Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun 382(4):776\u2013779. https:\/\/doi.org\/10.1016\/j.bbrc.2009.03.104","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"7545_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jdermsci.2017.01.008","volume":"86","author":"H Nakajima","year":"2017","unstructured":"Nakajima H, Serada S, Fujimoto M, Naka T, Sano S (2017) Leucine-rich alpha-2 glycoprotein is an innovative biomarker for psoriasis. J Dermatol Sci 86(2):170\u2013174. https:\/\/doi.org\/10.1016\/j.jdermsci.2017.01.008","journal-title":"J Dermatol Sci"},{"issue":"1","key":"7545_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12882-020-01782-0","volume":"21","author":"Y Yang","year":"2020","unstructured":"Yang Y, Luo R, Cheng Y, Liu T, Dai W, Li Y, Ge S, Xu G (2020) Leucine-rich alpha2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis. BMC Nephrol 21(1):122. https:\/\/doi.org\/10.1186\/s12882-020-01782-0","journal-title":"BMC Nephrol"},{"issue":"9","key":"7545_CR23","doi-asserted-by":"publisher","first-page":"e0257138","DOI":"10.1371\/journal.pone.0257138","volume":"16","author":"M Yanagimachi","year":"2021","unstructured":"Yanagimachi M, Fukuda S, Tanaka F, Iwamoto M, Takao C, Oba K, Suzuki N, Kiyohara K, Kuranobu D, Tada N, Nagashima A, Ishii T, Ino Y, Kimura Y, Nawa N, Fujiwara T, Naruto T, Morio T, Doi S, Mori M (2021) Leucine-rich alpha-2-glycoprotein 1 and angiotensinogen as diagnostic biomarkers for Kawasaki disease. PLoS One 16(9):e0257138. https:\/\/doi.org\/10.1371\/journal.pone.0257138","journal-title":"PLoS One"},{"issue":"5","key":"7545_CR24","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/mr\/road112","volume":"34","author":"M Fujimoto","year":"2024","unstructured":"Fujimoto M, Hosono Y, Serada S, Suzuki Y, Ohkawara T, Murata O, Quick A, Suzuki K, Kaneko Y, Takeuchi T, Naka T (2024) Leucine-rich alpha2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis. Mod Rheumatol 34(5):1072\u20131075. https:\/\/doi.org\/10.1093\/mr\/road112","journal-title":"Mod Rheumatol"},{"issue":"1","key":"7545_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","volume":"11","author":"S Shinzaki","year":"2017","unstructured":"Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T (2017) Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J Crohns Colitis 11(1):84\u201391. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw132","journal-title":"J Crohns Colitis"},{"issue":"9","key":"7545_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3346\/jkms.2014.29.9.1199","volume":"29","author":"YJ Ha","year":"2014","unstructured":"Ha YJ, Kang EJ, Lee SW, Lee SK, Park YB, Song JS, Choi ST (2014) Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis. J Korean Med Sci 29(9):1199\u20131204. https:\/\/doi.org\/10.3346\/jkms.2014.29.9.1199","journal-title":"J Korean Med Sci"},{"key":"7545_CR27","doi-asserted-by":"publisher","first-page":"3140204","DOI":"10.1155\/2019\/3140204","volume":"2019","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Yachie A (2019) Serum leucine-rich alpha2-glycoprotein as a biomarker for monitoring disease activity in patients with systemic juvenile idiopathic arthritis. J Immunol Res 2019:3140204. https:\/\/doi.org\/10.1155\/2019\/3140204","journal-title":"J Immunol Res"},{"issue":"19","key":"7545_CR28","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1002\/rcm.4237","volume":"23","author":"RG Kay","year":"2009","unstructured":"Kay RG, Barton C, Velloso CP, Brown PR, Bartlett C, Blazevich AJ, Godfrey RJ, Goldspink G, Rees R, Ball GR, Cowan DA, Harridge SD, Roberts J, Teale P, Creaser CS (2009) High-throughput ultra-high-performance liquid chromatography\/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Commun Mass Spectrom 23(19):3173\u20133182. https:\/\/doi.org\/10.1002\/rcm.4237","journal-title":"Rapid Commun Mass Spectrom"},{"key":"7545_CR29","doi-asserted-by":"publisher","unstructured":"Masood A, Benabdelkamel H, Ekhzaimy AA, Alfadda AA (2020) Plasma-based proteomics profiling of patients with hyperthyroidism after antithyroid treatment. Molecules 25 (12). https:\/\/doi.org\/10.3390\/molecules25122831","DOI":"10.3390\/molecules25122831"},{"issue":"7458","key":"7545_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature12345","volume":"499","author":"X Wang","year":"2013","unstructured":"Wang X, Abraham S, McKenzie JAG, Jeffs N, Swire M, Tripathi VB, Luhmann UFO, Lange CAK, Zhai Z, Arthur HM, Bainbridge J, Moss SE, Greenwood J (2013) LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 499(7458):306\u2013311. https:\/\/doi.org\/10.1038\/nature12345","journal-title":"Nature"},{"key":"7545_CR31","doi-asserted-by":"publisher","unstructured":"He S, Ryu J, Liu J, Luo H, Lv Y, Langlais PR, Wen J, Dong F, Sun Z, Xia W, Lynch JL, Duggirala R, Nicholson BJ, Zang M, Shi Y, Zhang F, Liu F, Bai J, Dong LQ (2021) LRG1 is an adipokine that mediates obesity-induced hepatosteatosis and insulin resistance. J Clin Invest 131 (24). https:\/\/doi.org\/10.1172\/JCI148545","DOI":"10.1172\/JCI148545"},{"key":"7545_CR32","doi-asserted-by":"publisher","unstructured":"Alhammad R, Abu-Farha M, Hammad MM, Thanaraj TA, Channanath A, Alam-Eldin N, Al-Sabah R, Shaban L, Alduraywish A, Al-Mulla F, Rahman A, Abubaker J (2022) Increased LRG1 levels in overweight and obese adolescents and its association with obesity markers, including leptin, chemerin, and high sensitivity C-reactive protein. Int J Mol Sci 23 (15). https:\/\/doi.org\/10.3390\/ijms23158564","DOI":"10.3390\/ijms23158564"},{"key":"7545_CR33","doi-asserted-by":"publisher","first-page":"1028994","DOI":"10.3389\/fimmu.2022.1028994","volume":"13","author":"A Sarkar","year":"2022","unstructured":"Sarkar A, Chakraborty D, Kumar V, Malhotra R, Biswas S (2022) Upregulation of leucine-rich alpha-2 glycoprotein: a key regulator of inflammation and joint fibrosis in patients with severe knee osteoarthritis. Front Immunol 13:1028994. https:\/\/doi.org\/10.3389\/fimmu.2022.1028994","journal-title":"Front Immunol"},{"issue":"7","key":"7545_CR34","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/art.41640","volume":"73","author":"EL Verweyen","year":"2021","unstructured":"Verweyen EL, Pickering A, Grom AA, Schulert GS (2021) Distinct gene expression signatures characterize strong clinical responders versus nonresponders to canakinumab in children with systemic juvenile idiopathic arthritis. Arthritis Rheumatol 73(7):1334\u20131340. https:\/\/doi.org\/10.1002\/art.41640","journal-title":"Arthritis Rheumatol"},{"key":"7545_CR35","doi-asserted-by":"publisher","first-page":"9259646","DOI":"10.1155\/2016\/9259646","volume":"2016","author":"P Rider","year":"2016","unstructured":"Rider P, Carmi Y, Cohen I (2016) Biologics for targeting inflammatory cytokines, clinical uses, and limitations. Int J Cell Biol 2016:9259646. https:\/\/doi.org\/10.1155\/2016\/9259646","journal-title":"Int J Cell Biol"},{"key":"7545_CR36","doi-asserted-by":"publisher","first-page":"8825374","DOI":"10.1155\/2021\/8825374","volume":"2021","author":"T Yoshimura","year":"2021","unstructured":"Yoshimura T, Mitsuyama K, Sakemi R, Takedatsu H, Yoshioka S, Kuwaki K, Mori A, Fukunaga S, Araki T, Morita M, Tsuruta K, Yamasaki H, Torimura T (2021) Evaluation of serum leucine-rich alpha-2 glycoprotein as a new inflammatory biomarker of inflammatory bowel disease. Mediators Inflamm 2021:8825374. https:\/\/doi.org\/10.1155\/2021\/8825374","journal-title":"Mediators Inflamm"},{"key":"7545_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jns.2018.07.006","volume":"392","author":"PF Chong","year":"2018","unstructured":"Chong PF, Sakai Y, Torisu H, Tanaka T, Furuno K, Mizuno Y, Ohga S, Hara T, Kira R (2018) Leucine-rich alpha-2 glycoprotein in the cerebrospinal fluid is a potential inflammatory biomarker for meningitis. J Neurol Sci 392:51\u201355. https:\/\/doi.org\/10.1016\/j.jns.2018.07.006","journal-title":"J Neurol Sci"},{"issue":"9","key":"7545_CR38","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1136\/ard.2006.063834","volume":"66","author":"T Matsui","year":"2007","unstructured":"Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, Yasuda M, Saisho K, Shimada K, Tohma S (2007) Disease activity score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 66(9):1221\u20131226. https:\/\/doi.org\/10.1136\/ard.2006.063834","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7545_CR39","doi-asserted-by":"publisher","first-page":"e24231","DOI":"10.1002\/jcla.24231","volume":"36","author":"K He","year":"2022","unstructured":"He K, He S, Su M (2022) Inter-alpha-trypsin inhibitor heavy chain 4: a serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis. J Clin Lab Anal 36(3):e24231. https:\/\/doi.org\/10.1002\/jcla.24231","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"7545_CR40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s10787-021-00823-w","volume":"29","author":"D Song","year":"2021","unstructured":"Song D, Zhu X, Wang F, Sun J (2021) Longitudinal monitor of Jun N-terminal kinase pathway associated phosphatase reflects clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs treatment in rheumatoid arthritis patients. Inflammopharmacology 29(4):1131\u20131138. https:\/\/doi.org\/10.1007\/s10787-021-00823-w","journal-title":"Inflammopharmacology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07545-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:50:14Z","timestamp":1756453814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07545-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7545"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07545-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures have been approved by the ethics committee of Wuhan No.1 Hospital and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants signed the informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}